Abstract: In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

Abstract: Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

Abstract: This process manufactures a finished medicine that can be used against broad spectrum, Anti-Viral, Anti-Bacterial, Anti-Fungal, and Anti-parasitic disease conditions that attack the human body but not limited to other medical conditions and or other types of treatments use for animals other than humans.

Abstract: An application of alginate sulfate in the preparation of drugs and health care products for preventing and treating diseases caused by human papillomavirus. Alginate sulfate has a strong dose-dependent inhibitory effect on HPV infection through experiments, and alginate sulfate inhibited the expression of E6 and E7 genes and proteins in HPV-transformed Hela and Caski cells in a dose-dependent manner. The alginate sulfate can be developed into a drug or a health care product against human papillomavirus by systematic scientific experiments, which will have a good market application prospect.

Abstract: Provided herein are compositions (e,g., pharmaceutical compositions) comprising deuterated testosterone, deuterated methyltestosterone, or derivatives thereof. The provided compositions and related methods may be useful for treating and/or preventing various diseases and conditions, such as hypogonadism, delay of growth and puberty, weight loss associated with HIV-associated wasting, vulvar dystrophies, micropenis, breast cancer, and sexual disorders.

Abstract: A method of controlling anthracnose caused by Colletotrichum on tropical fruits, tropical fruit plants or cultivars or plant parts or locus thereof is described. The method comprises the steps of contacting the tropical fruit plant or cultivar in need of treatment with an agrochemical composition comprising an effective amount of a guanidine or a salt and/or solvate thereof. The contacting step may be repeated one or more times at a fixed interval. The guanidine may be dodine, iminoctadine trialbesilate, iminoctadine triacetate, guazatine, salts and/or solvates of any of the foregoing and combinations of one or more of the foregoing.

Abstract: A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to produce a film coating suspension. The film coating suspension can be applied to a substrate, such as a nutritional supplement, pharmaceutical, tablet, capsule, softgel, granule, particle, food confectionary form, agricultural seed, and the like to form a film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided.

Abstract: The present invention provides an ophthalmic gel and a preparation method thereof. The ophthalmic gel comprises: an antibiotic; a nanocarrier, wherein the nanocarrier is used to load the antibiotic; and a biodegradable matrix, wherein the biodegradable matrix is compatible with the nanocarrier to carry the nanocarrier. When the ophthalmic gel of the present invention is applied to the surface of the cornea and conjunctiva of the eyes, the biodegradable matrix is automatically degraded and the nanocarrier carried by the biodegradable matrix will slowly release the antibiotic, loaded in the nanocarrier, at an appropriate rate to overcome the high-frequency use of general ophthalmic drugs and easily caused blurred vision; the present invention further comprises an ophthalmic gel preparation method.

Abstract: This document discloses a powder formulation of tadalafil for oral administration. Also disclosed are a method of preparing the powder formulation, a suspension dosage form of tadalafil and a method of treating diseases.

Abstract: Techniques regarding the transportation of molecular cargo across the BBB are provided. For example, one or more embodiments described herein can comprise a chemical compound to facilitate molecular encapsulation of the molecular cargo. The chemical compound can comprise a diblock copolymer having a molecular backbone comprising a polycarbonate structure and a polyethylene glycol structure. Also, the polycarbonate structure can be functionalized with boronic acid.

Abstract: The present invention relates to an oral soluble film (OSF), methods of orally administering the same, and methods of manufacturing the same. The oral soluble film includes sildenafil citrate, and can further include a binder, filler, flavoring agent, plasticizer, sweetening agent, preservative, solvent, and optionally coloring agent. The active ingredient and excipients can be provided and present in an amount effective to achieve desired physical and performance characteristics of the OSF.

Abstract: Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

Abstract: Various examples of systems and methods for making microspheres, microparticles, and emulsions are provided. In one example, a system and method for forming microspheres comprises: pumping a dispersed phase liquid and a continuous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase liquid and continuous phase liquid to a high shear environment within the impeller pump's pump chamber. In another example, a system and method for forming an emulsion comprises: pumping a dispersed phase liquid and an inner aqueous phase liquid into a levitating magnetic impeller pump to subject the dispersed phase and the inner aqueous phase to a high shear environment within the impeller pump's pump chamber.

Abstract: An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt.

Abstract: Disclosed is a microcapsule containing: (i) a microcapsule core having an active material, and (ii) a microcapsule wall formed of a first polymer and second polymer. The first polymer is a sol-gel polymer. The second polymer is gum arabic, purity gum ultra, gelatin, chitosan, xanthan gum, plant gum, carboxymethyl cellulose, sodium carboxymethyl guar gum, or a combination thereof. The weight ratio between the first and second polymer is 1:10 to 10:1. Also disclosed are processes for preparing the microcapsule and uses of the microcapsules in consumer products.

Abstract: The invention provides a nanoemulsion adjuvant and a preparation method thereof, which are composed of the following components: a continuous aqueous phase containing H2O molecules, an oil phase material containing fats and oils, and an emulsion system for stabilizing the interface between the continuous aqueous phase and the oil phase, and the emulsion system is an emulsifier mixture. The adjuvant is characterized in that the emulsion system does not contain an ionic emulsifier and the particle size of the emulsion is between 20 and 200 nanometers. The use of the nanoemulsion adjuvant can prevent toxicity and possible harm of ionic emulsifiers to human cells, and provide a vaccine preparation capable of eliciting a high degree of immune response.

Abstract: The present application relates to an amphiphilic polymer and a method for producing the same. The present application also relates to micelles comprising the amphiphilic polymer and a method for producing the same. The amphiphilic polymer of the present application can have excellent dispersion properties while effectively encapsulating the drug.

Abstract: A water-based liquid cosmetic containing diethylhexyl sodium sulfosuccinate, an inorganic coloring pigment, a water-soluble dispersant, and a film-forming polymer emulsion, wherein a content of diethylhexyl sodium sulfosuccinate is 0.01 to 1 mass % and a content of the inorganic coloring pigment is 3 to 20 mass %, based on a total amount of the cosmetic, and wherein the inorganic coloring pigment contains carbon black.

Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water. The present invention provides a freeze-dried aripiprazole formulation obtained by a process comprising the steps of spraying for freezing an aripiprazole suspension containing (I) aripiprazole, (II) a vehicle for the aripiprazole, and (III) water for injection, and drying.

Abstract: Methods of treating water to promote the health of aquatic organisms are described. The method may include introducing pulverized kaolin into the water. The pulverized kaolin may have a particle size distribution such that at least 30% by weight of the particles pass through a 60 mesh screen. For example, the pulverized kaolin may be in the form of a dry powder having a d50 diameter less than 300 ?m. The pulverized kaolin may remain dispersed or suspended in the water without dispersants and/or surfactants, e.g., to reduce the amount of at least one pathogenic microorganism present in the water and/or to reduce or prevent exposure of aquatic organisms to the pathogenic microorganism(s).

Abstract: A chloroquine gel and a preparation method and application thereof. A chloroquine nanosphere includes a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative, wherein a mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier is no more than 1:3.

Abstract: A medicated hard candy product for treating eosinophilic esophagitis (EoE) is disclosed herein. The medicated hard candy product includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material. The medicated hard candy product is configured to reduce or alleviate esophageal inflammation and/or symptoms associated therewith in an individual when orally administered thereto. In one or more embodiments, the corticosteroid comprises one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate. Also, in one or more embodiments, the medicated hard candy product is in the form of a lollipop or lozenge.

Abstract: The present invention relates to a composition containing extracellular vesicles derived from plant juice, wherein the extracellular vesicles have excellent skin condition-improving effects such as skin whitening, moisturizing and wrinkle reducing effects and exhibits an excellent effect of preventing hair loss by promotion of hair growth and regrowth, and the like.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

Abstract: The present disclosure generally relates to a combination dry powder inhaler (DPI) formulation of Ciprofloxacin and Colistin through co-spray drying, particularly to a co-sprayed colistin and Ciprofloxacin dry powder inhaler for the treatment of various bacterial infections. Methods of use and composition matters are within the scope of this disclosure.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: Provided herein are compositions and methods for wound healing. In particular, provided herein are spray dried suramin for use in wound healing and other applications.

Abstract: The invention pertains to the field of nanotechnology. More particularly, the invention relates to highly luminescent nanostructures, particularly highly luminescent nanostructures comprising a ZnTe core and CdS, CdSe, CdTe, ZnS, ZnSe, or ZnTe shell layers. The nanostructures show strong absorbance at 450 nm and have a high OD450/mass ratio. The invention also relates to methods of producing such nanostructures.

Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Abstract: Biodegradable, cross-linked polymer films and methods of making the same are described. The polymer films can be used for preventing adhesions following surgery and/or delivering therapeutic agents.

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

Abstract: Peptide that regulates fat metabolism and is used in the preparation of a medicament for the treatment of diseases associated with abnormalities in energy metabolism is described, particularly fat metabolism. The peptide of the present disclosure can reduce fat absorption, reduce fat accumulation in the liver and regulate fat metabolism, and has an advantage of being orally administered as compared with other general peptide products, and thus can also be used as an active ingredient of a health care product for regulating fat metabolism.

Abstract: Provided herein are nanoparticles comprising a polyplex core comprising one or more pH-responsive polymers and one or more anionic immune adjuvants, wherein each pH-responsive polymer comprises ionizable amine groups; and a shell of bacterial cell membrane components at least partially coating the polyplex core, wherein the bacterial cell membrane components comprise TLR 2 and/or TLR 4 agonists. Also provided are methods of stimulating an immune response in a mammal using the nanoparticle.

Abstract: A recycled pulp that is reusable sanitary products is efficiently manufactured by recovering pulp fiber from used sanitary products containing the pulp fiber and a polymer absorbent. The method of the present invention comprises: a step applying a mechanical force to the used sanitary products in an aqueous solution containing a polyvalent metal ion or an acidic aqueous solution with a pH of 2.5 or lower and thus degrading the used sanitary products into the pulp fiber and other materials; a step separating the pulp fiber from the mixture of the pulp fiber and other materials that has been formed in the degradation step; and a step treating the pulp fiber thus separated with an ozone-containing aqueous solution with a pH of 2.5 or lower.

Abstract: It relates to a lurasidone solid dispersion and a preparation method, wherein the method comprises melting treatment of a mixture containing lurasidone, a medicinal hot melt carrier, optionally an acidic regulator and plasticizer in order to obtain the solid dispersion described herein, and wherein the lurasidone is provided in a form of free base. The lurasidone solid dispersion obtained by the preparation method according to the example of the invention has the characteristics of high dissolution rate (dissolution rate can reach 30%-70%) in a partial neutral medium (e.g. pH6.0). The bioavailability of lurasidone solid dispersion increased significantly and the food effect of lurasidone solid dispersion prepared from the example decreased remarkably.

Abstract: In accordance with one aspect, embolic particles are provided which comprise sub-particles that comprise a therapeutic agent of low solubility dispersed in a matrix that comprises a biodegradable polymer. Other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. Still other aspects pertain to methods of making such particles.

Abstract: Cosmetic compositions having durable gloss, such as cosmetic lipcolors, are provided. The compositions comprise a gel formed from a cellulosic polymer and a polar oil, a non-polar film-forming agent, polyhydroxystearic acid, and optionally one or more pigments. The compositions may have one or more properties selected from long-wear, oil transfer resistance, water transfer resistance, comfort, and durable shine.

Abstract: Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof.

Abstract: This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.

Abstract: A patch for treating vascular ulcers caused by excessive enzymatic activity may include a substrate configured to span a vascular ulcer as well as a linking material that is disposed relative to the substrate and has an affinity for an enzyme involved in causing the vascular ulcer. A magnetic material may be coupled to the linking material. In some cases, the enzymes involved in causing the vascular ulcer may become coupled to the linking material and thus become coupled to the magnetic material so that that the enzymes can be removed by applying a magnetic field in the proximity of the vascular ulcer. The enzymes may include matrix metalloproteinases.

Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.

Abstract: A chain-reactive, heat-generating microcapsule comprises a first compartment including a first component and a second compartment including a second component. An isolating structure separates the first and second compartments. The isolating structure may rupture when heated above a normal ambient temperature and/or in response to a compressive force. The first component reacts with the second component to produce heat. The microcapsule may further incorporate a blowing agent that responds to heating. In some embodiments, a core within the first compartment comprises a blowing agent material that responds to the heat produced when the first and second components react. The microcapsules can be incorporated into a material comprising a heat-curable resin precursor such that heat generated by the microcapsules can be used to cure the resin precursor.

Abstract: Provided, inter alia, are synthetic melanin nanoparticles (MelNPs) useful for protecting keratinocytes from UV-damage and for treating melanin-defective diseases.

Abstract: Described herein are compositions that include a saline solution and reactive oxygen species. Specifically, the composition may include a saline solution, reactive oxygen species, an emollient, and a pH modifier. Also provided is a gel composition that includes a rheology agent. Also provided are methods of making and using the compositions.

Abstract: The present invention provides a separator for microorganisms in cavitary contents. The separator for microorganisms in cavitary contents includes a raw material vessel, a stage filter, a liquid storage vessel, a closed separated material vessel, a separate loading unit, a deodorizer, pipelines for connecting all the units, etc.

Abstract: In embodiments a metal or metal alloy nanowires are assembled into a nanoporous membrane that can be used in methods for catalyzing various reactions under low pressures and achieving high flow rate of the reactions. In embodiments, the membranes of the disclosure can catalyze CuAAC reactions with high efficiency and minimum leaching of active Cu species.

Abstract: A flowable birth tissue composition fabricated from birth tissue is provided. Methods of processing a mammal's placental tissue to form a flowable birth tissue composition are provided. Various methods of treatment and uses are also provided.

Abstract: Disclosed is a novel antimicrobial means which is effective against various types of fungi including pathogenic true fungi and phytopathogenic filamentous fungi. An antimicrobial agent against fungi according to the present invention comprises, as an effective ingredient, cyanoacrylate polymer particles having an average particle diameter of less than 1000 nm, which particles contain at least one selected from the group consisting of amino acids, amino acid derivatives, oligomers and polymers thereof, saccharides and polysorbates, and contain no antimicrobial active ingredient effective against the fungi. The antimicrobial agent is particularly useful as a control agent against plant diseases caused by filamentous fungi.

Abstract: Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 ?m to 1000 ?m deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.